Throughout its 40-year history, the field of gene therapy has been marked by many
transitions. It has seen great strides in combating human disease, has given hope to patients …

Ever since the development of the first vaccine more than 200 years ago, vaccinations have
greatly decreased the burden of infectious diseases worldwide, famously leading to the …

Background A vaccine to protect against COVID-19 is urgently needed. We aimed to assess
the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) …

Human diseases, particularly infectious diseases and cancers, pose unprecedented
challenges to public health security and the global economy. The development and …

With rapid advances in understanding molecular pathogenesis of human diseases in the era
of genome sciences and systems biology, it is anticipated that increasing numbers of …

Importance Developing effective vaccines against Ebola virus is a global priority. Objective
To evaluate an adenovirus type 26 vector vaccine encoding Ebola glycoprotein (Ad26 …

Background The safety and efficacy of vaccines to prevent Ebola virus disease (EVD) were
unknown when the incidence of EVD was peaking in Liberia. Methods We initiated a …

Background The unprecedented 2014 epidemic of Ebola virus disease (EVD) prompted an
international response to accelerate the availability of a preventive vaccine. A replication …

At the current time, the field of vaccinology remains empirical in many respects. Vaccine
development, vaccine immunogenicity, and vaccine efficacy have, for the most part …

Background A recombinant adenovirus type-5 vector-based vaccine expressing the
glycoprotein of Ebola Zaire Makona variant showed good safety and immunogenicity in a …